Press Release: Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering

Dow Jones04-19

Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering

SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO, the "Company" or "Histogen"), a drug development company for treatment of bacterial skin infections, today announced that it has filed voluntary petitions for relief under subchapter V of Chapter 11 of the U.S. Bankruptcy Code ("Chapter 11") in the United States Bankruptcy Court for the Southern District of California to confirm a plan of liquidation that will distribute all value to stakeholders, including shareholders.

Histogen intends to promptly propose and confirm a plan of liquidation and make distributions to the benefit of its estate. The Company announced on Sept. 18, 2023, that it had discontinued further development and would seek approve for a Plan of Dissolution.

Histogen is represented by DLA Piper, LLP as its legal counsel and Armanino LLP as its financial advisor.

ABOUT HISTOGEN

Histogen Inc. was a clinical-stage therapeutics company focused on developing potential clinical and preclinical drugs for a variety of antiapoptotic and anti-inflammatory effects.

MEDIA CONTACT 
Martin Stein 
AMF Media Group 
martin@amfmediagroup.com

(END) Dow Jones Newswires

April 18, 2024 18:02 ET (22:02 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2428525375?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-19 06:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2428525375","market":"sh","top_or_hot":-1,"title":"Press Release: Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering \n</p>\n<p>\n  SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO, the \"Company\" or \"Histogen\"), a drug development company for treatment of bacterial skin infections, today announced that it has filed voluntary petitions for relief under subchapter V of Chapter 11 of the U.S. Bankruptcy Code (\"Chapter 11\") in the United States Bankruptcy Court for the Southern District of California to confirm a plan of liquidation that will distribute all value to stakeholders, including shareholders. \n</p>\n<p>\n  Histogen intends to promptly propose and confirm a plan of liquidation and make distributions to the benefit of its estate. The Company announced on Sept. 18, 2023, that it had discontinued further development and would seek approve for a Plan of Dissolution. \n</p>\n<p>\n  Histogen is represented by DLA Piper, LLP as its legal counsel and Armanino LLP as its financial advisor. \n</p>\n<p>\n  ABOUT HISTOGEN \n</p>\n<p>\n  Histogen Inc. was a clinical-stage therapeutics company focused on developing potential clinical and preclinical drugs for a variety of antiapoptotic and anti-inflammatory effects. \n</p>\n<pre>\nMEDIA CONTACT \nMartin Stein \nAMF Media Group \nmartin@amfmediagroup.com \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 18, 2024 18:02 ET (22:02 GMT)\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-19 06:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering \n\n\n  SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO, the \"Company\" or \"Histogen\")...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2428525375","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428525375","pubTimestamp":1713477720,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"SAN DIEGO, April 18, 2024  -- Histogen Inc. , a drug development company for treatment of bacterial skin infections, today announced that it has filed voluntary petitions for relief under subchapter V of Chapter 11 of the U.S. Bankruptcy Code  in the United States Bankruptcy Court for the Southern District of California to confirm a plan of liquidation that will distribute all value to stakeholders, including shareholders.Histogen intends to promptly propose and confirm a plan of liquidation and make distributions to the benefit of its estate. The Company announced on Sept. 18, 2023, that it had discontinued further development and would seek approve for a Plan of Dissolution.Histogen is represented by DLA Piper, LLP as its legal counsel and Armanino LLP as its financial advisor.Histogen Inc. was a clinical-stage therapeutics company focused on developing potential clinical and preclinical drugs for a variety of antiapoptotic and anti-inflammatory effects.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","HSTO":"Histogen Inc."},"translate_title":"新闻稿：组织原文件自愿第11章保护，以促进清盘，最大限度地提供股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HSTO":0.9},"content_text":"Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering \n\n\n  SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO, the \"Company\" or \"Histogen\"), a drug development company for treatment of bacterial skin infections, today announced that it has filed voluntary petitions for relief under subchapter V of Chapter 11 of the U.S. Bankruptcy Code (\"Chapter 11\") in the United States Bankruptcy Court for the Southern District of California to confirm a plan of liquidation that will distribute all value to stakeholders, including shareholders. \n\n\n  Histogen intends to promptly propose and confirm a plan of liquidation and make distributions to the benefit of its estate. The Company announced on Sept. 18, 2023, that it had discontinued further development and would seek approve for a Plan of Dissolution. \n\n\n  Histogen is represented by DLA Piper, LLP as its legal counsel and Armanino LLP as its financial advisor. \n\n\n  ABOUT HISTOGEN \n\n\n  Histogen Inc. was a clinical-stage therapeutics company focused on developing potential clinical and preclinical drugs for a variety of antiapoptotic and anti-inflammatory effects. \n\n\nMEDIA CONTACT \nMartin Stein \nAMF Media Group \nmartin@amfmediagroup.com \n\n\n  (END) Dow Jones Newswires\n\n\n  April 18, 2024 18:02 ET (22:02 GMT)","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428525375"}